A Senate-passed bill to legalize possession of certain psychedelics in California cleared a procedural hurdle on Monday—but it faces another critical challenge in the Assembly next week that could decide its fate.
Exploring the companies and themes that make up this emerging and exciting new sector
MindMed Joins Critical Path Institute's Patient-Reported Outcome Consortium
MindMed announces joining a research consortium, the Patient-Reported Outcome Consortium, to assist in its mission to advance medical innovation.
Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and Receives a Favorable Patent Claim Opinion
Cybin announces the filing of a non-provisional patent application, the company's 14th patent application.
MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline
MindMed reports a Q2 2021 loss of $36 million. Current cash on hand of $157 million.
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions
ATAI's newest research partner, Revixia Life Sciences, is seeking to treat depression and substance abuse with Salvinorin A, a lesser-known psychedelic used by indigenous peoples.
Is Access To Psychedelic Medicine The Largest Human Rights Issue Today?
The Mental Health Crisis is now a mental health pandemic. Is access to psychedelic medicine the world's largest human rights issue?
COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021
Compass Pathways reports a Q2 loss of $17.5 million and announces raising $154.8 million in a new financing in May.
Wesana Health Commences Functional Animal Study for Treatment of Traumatic Brain Injury
Wesana Health announces the commencement of pre-clinical psychedelics research for Traumatic Brain Injury.
Psychedelic Medicine vs. Conventional Mental Health Therapies: Cures vs. Crutches
Two billion people have treatable mental health disorders. Where existing therapies are merely inadequate crutches, psychedelic drugs can produce cures.
Do you know the mushroom man?
Many places across the state recorded the rainiest July on record—that was great news for Kevyn Fowler.
Which Psychedelic Drug Has The Most Commercial Potential?
Psychedelic Stock Watch compares and contrasts the drug development opportunities with psychedelic drugs (and psychedelic drug stocks).
MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor
MINDCURE announces that renowned human rights activist, Jerry White, has joined the company as an advisor. Winner of the Nobel Peace Prize, White will help MINDCURE revolutionize mental health.